Standout Papers

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderat... 2021 2026 2022 2024199
  1. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial (2021)
    Sarah Diver, Latifa Khalfaoui et al. The Lancet Respiratory Medicine

Immediate Impact

56 standout
Sub-graph 1 of 21

Citing Papers

Engineered commensals for targeted nose-to-brain drug delivery
2025 Standout
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
2025 Standout
3 intermediate papers

Works of Sarah Diver being referenced

Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus‐predominant subgroup
2019
Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles
2018

Author Peers

Author Last Decade Papers Cites
Sarah Diver 391 289 130 19 521
Antonella Di Franco 448 382 61 26 649
Manuel Soto-Quirós 370 222 119 14 572
John M. Fahrenholz 444 202 191 18 568
L. C. Martinati 420 224 98 24 535
Paolo Morelli 362 346 88 12 527
Miguel J. Lanz 525 328 136 30 604
Stelios Pavlidis 351 281 241 22 634
Louis Philippe Boulet 437 414 57 10 604
Kristina Irander 271 126 77 24 498
Nikolina Icitovic 384 271 127 11 495

All Works

Loading papers...

Rankless by CCL
2026